AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35838778 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG accompanied by medical clowns (study group)
Number of subjects: 100
Study 35838778 — intervention group
Group type: COMPARATOR
Intervention: Routine EEG without medical clowns (control group)
Number of subjects: 100
Study 33279173 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP
Number of subjects: 78
Study 33279173 — intervention group
Group type: COMPARATOR
Intervention: ABP
Number of subjects: 78
Study 34985237 — intervention group
Group type: COMPARATOR
Intervention: Hip and knee strengthening at 70% of 1 repetition maximum
Number of subjects: 60
Study 34985237 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening with blood flow restriction at 30% of 1 repetition maximum at 70% of limb occlusion pressure
Number of subjects: 60
Study 32660512 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video game-based exercise (IVGB) training during the intervention phase
Number of subjects: 24
Study 32660512 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no exercise)
Number of subjects: 24
Study 35567757 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bicyclol (25 mg TID)
Number of subjects: 241
Study 35567757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bicyclol (50 mg TID)
Number of subjects: 241
Study 35567757 — intervention group
Group type: COMPARATOR
Intervention: Control (polyenes phosphatidylcholine)
Number of subjects: 241
Study 33858668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Enteral Feeding
Number of subjects: 0
Study 33858668 — intervention group
Group type: COMPARATOR
Intervention: Traditional Feeding
Number of subjects: 0
Study 36247895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group K (120 kV/40–59 mA/8) for CT imaging
Number of subjects: 100
Study 36247895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group i (0.15 mCi/kg/180 s) for PET imaging
Number of subjects: 100
Study 36247895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (80 kV/40–59 mA/14) for CT scanning
Number of subjects: 100
Study 36247895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group g (0.08 mCi/kg/180 s) for PET imaging
Number of subjects: 100
Study 33387385 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression-specific preventive intervention
Number of subjects: 213
Study 33387385 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study 33387385 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowed gait
Number of subjects: 213
Study 33387385 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowed psychomotor speed
Number of subjects: 213
Study 36311474 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + IP
Number of subjects: 72
Study 36311474 — intervention group
Group type: COMPARATOR
Intervention: SOC + Placebo
Number of subjects: 72
Study 35283082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception (various methods including implants, IUDs, combined pills, progestin-only pills, injectables, ring, patch)
Number of subjects: 138
Study 35283082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception (various methods)
Number of subjects: 138
Study 33990145 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cardiopulmonary ultrasonography (ICUS)
Number of subjects: 94
Study 33990145 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CON)
Number of subjects: 94
Study 36201384 — intervention group
Group type: EXPERIMENTAL
Intervention: Deposit contract (€10 deposit up front)
Number of subjects: 126
Study 36201384 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reward (€10 contingent on performance)
Number of subjects: 126
Study 36201384 — intervention group
Group type: COMPARATOR
Intervention: No-incentive control condition
Number of subjects: 126
Study 36201384 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss frame
Number of subjects: 126
Study 36201384 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain frame
Number of subjects: 126
Study 34366380 — intervention group
Group type: EXPERIMENTAL
Intervention: Foslevodopa/foscarbidopa administered via abdominal SC infusion over 72 hours
Number of subjects: 28
Study 34366380 — intervention group
Group type: EXPERIMENTAL
Intervention: Foslevodopa/foscarbidopa infusion
Number of subjects: 28
Study 34366380 — intervention group
Group type: EXPERIMENTAL
Intervention: Foslevodopa/foscarbidopa
Number of subjects: 28
Study 32481510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockosorb® (STS) at 0.3% mixed with soil + root
Number of subjects: 0
Study 32481510 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium seed mucilage (PSM) at 0.3% mixed with soil + root
Number of subjects: 0
Study 32481510 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium seed mucilage (PSM) at 0.1% mixed with soil + root
Number of subjects: 0
Study 32481510 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium seed mucilage (PSM) at 0.1% and 0.2% mixed with soil + root
Number of subjects: 0
Study 32481510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockosorb® (STS) at 0.2% mixed with soil + root
Number of subjects: 0
Study 32481510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockosorb® (STS) mixed with soil
Number of subjects: 0
Study 32481510 — intervention group
Group type: COMPARATOR
Intervention: Control (no hydrophilic polymers)
Number of subjects: 0
Study 34446067 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB 3 gm/day
Number of subjects: 83
Study 34446067 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 2 gm/day
Number of subjects: 83
Study 34446067 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB plus EPA
Number of subjects: 83
Study 34446067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 32186521 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips' Guardian system (mean NPS score 8.8, SD 0.89)
Number of subjects: 37
Study 32186521 — intervention group
Group type: EXPERIMENTAL
Intervention: eTrAC system (mean NPS score 7.7 for nurses, mean NPS score 9.2 for patients)
Number of subjects: 37
Study 32186521 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NPS scores
Number of subjects: 37
Study 33333055 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 levels assessed in subjects at risk for pancreatic cancer
Number of subjects: 175
Study 33333055 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 levels assessed in subjects with resectable pancreatic cancer
Number of subjects: 175
Study 33333055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 with LRG1 and TIMP1
Number of subjects: 175
Study 33036655 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I delivered via smartphone application proACT-S
Number of subjects: 285
Study 33036655 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 285
Study 34097005 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Excision (LE)
Number of subjects: 0
Study 34097005 — intervention group
Group type: COMPARATOR
Intervention: Total Mesorectal Excision (TME)
Number of subjects: 0
Study 34097005 — intervention group
Group type: COMPARATOR
Intervention: Completion TME
Number of subjects: 0
Study 32697889 — intervention group
Group type: EXPERIMENTAL
Intervention: SCThrive intervention (six weekly group sessions, in-person booster session, companion app usage)
Number of subjects: 53
Study 32697889 — intervention group
Group type: COMPARATOR
Intervention: SCHealthEd intervention (six weekly phone calls on SCD-related and general health education topics)
Number of subjects: 53
Study 35908849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBT)
Number of subjects: 180
Study 35908849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin/montelukast (GBT/MTL)
Number of subjects: 180
Study 35908849 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan (DXM)
Number of subjects: 180
Study 33836405 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 132
Study 33836405 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 132
Study 33836405 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 132
Study 35753247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% pure oxygen inhalation (hyperoxic CHRS testing)
Number of subjects: 10
Study 35753247 — intervention group
Group type: COMPARATOR
Intervention: Cold face test (CFT)
Number of subjects: 10
Study 35753247 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 10
Study 34171465 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic technique transforaminal lumbar interbody fusion (BE‐TLIF)
Number of subjects: 102
Study 34171465 — intervention group
Group type: COMPARATOR
Intervention: Microscopic tubular technique transforaminal lumbar interbody fusion (MT‐TLIF)
Number of subjects: 102
Study 34171465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BE‐TLIF and MT‐TLIF
Number of subjects: 102
Study 35048150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofat mixed with platelet-rich plasma (PRP) infiltrations (2 at 3-month intervals)
Number of subjects: 20
Study 35048150 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid therapy
Number of subjects: 20
Study 34618511 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Screening, Education, and Brief Intervention (Adapted SBI)
Number of subjects: 58
Study 34618511 — intervention group
Group type: COMPARATOR
Intervention: Screening and Education with Attention Control (SEA)
Number of subjects: 58
Study 34618511 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (Adapted SBI and SEA)
Number of subjects: 58
Study 32699919 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-strand semitendinosus (4ST) graft with adjustable femoral and tibial cortical fixation
Number of subjects: 60
Study 32699919 — intervention group
Group type: COMPARATOR
Intervention: ST/gracilis (ST/G) graft with femoral pin transfixation and tibial bioscrew fixation
Number of subjects: 60
Study 32699919 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-strand semitendinosus (4ST) graft
Number of subjects: 60
Study 32699919 — intervention group
Group type: COMPARATOR
Intervention: ST/gracilis (ST/G) graft
Number of subjects: 60
Study 34852266 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal fresh gas flow (FGF) sevoflurane anesthesia (0.5 L.min−1)
Number of subjects: 204
Study 34852266 — intervention group
Group type: COMPARATOR
Intervention: High fresh gas flow (FGF) sevoflurane anesthesia (2.0 L.min−1)
Number of subjects: 204
Study 34852266 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal fresh gas flow (FGF) sevoflurane anesthesia
Number of subjects: 204
Study 33208708 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VF, 150-375 mg/d)
Number of subjects: 234
Study 32854000 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-reinforcing contingency management (CM) intervention
Number of subjects: 73
Study 32854000 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study 35088752 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous stimulation
Number of subjects: 20
Study 35088752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute on:1 minute off
Number of subjects: 20
Study 35088752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute on:2 minutes off
Number of subjects: 20
Study 33191117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging (MRI) at 3 months from enrollment, followed by fusion-target biopsy if positive (PIRADS-v2>2).
Number of subjects: 124
Study 33191117 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent PRIAS protocol including a confirmatory 12-core random biopsy at 12 months.
Number of subjects: 124
Study 32626890 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical flap group
Number of subjects: 98
Study 32626890 — intervention group
Group type: COMPARATOR
Intervention: Surgical flap group
Number of subjects: 98
Study 32626890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study 34903403 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program based on health belief model (6 sessions)
Number of subjects: 64
Study 34903403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training during the study)
Number of subjects: 64
Study 34129365 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737
Study 33109394 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation treatment + enhanced cue‐based treatment (interactive texting and cue management counseling)
Number of subjects: 24
Study 33109394 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation treatment
Number of subjects: 24
Study 33109394 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation treatment + enhanced cue‐based treatment
Number of subjects: 24
Study 36375975 — intervention group
Group type: EXPERIMENTAL
Intervention: GRRAND intervention (physiotherapy programme)
Number of subjects: 8
Study 36375975 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8
Study 32062371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hydrocortisone (LDH 10 mg)
Number of subjects: 65
Study 32062371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality nutrition service delivery during ANC
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Good logistical readiness of the facilities
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation by paramedics
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation by community health care providers
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: HCPs' knowledge on maternal nutrition
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Better HCP‐client communication
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of visual aids or ANC card
Number of subjects: 1242
Study 35085319 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP training and external supervision
Number of subjects: 1242
Study 32284387 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education support programme (2-day group course plus nurse-led consultation and follow-up over 8 weeks)
Number of subjects: 689
Study 32284387 — intervention group
Group type: COMPARATOR
Intervention: Usual care and relaxation programme
Number of subjects: 689
Study 36224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.025 μg/(kg·min)
Number of subjects: 200
Study 36224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.050 μg/(kg·min)
Number of subjects: 200
Study 36224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.075 μg/(kg·min)
Number of subjects: 200
Study 36224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.100 μg/(kg·min)
Number of subjects: 200
Study 36224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.125 μg/(kg·min)
Number of subjects: 200
Study 36224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 200
Study 32584367 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) plus capecitabine (at phase 1 MTD of 700 mg/m2)
Number of subjects: 161
Study 32584367 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) alone
Number of subjects: 161
Study 35020932 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartBar (260 kcal, 7E% fat, 74E% carbohydrate, 19E% protein)
Number of subjects: 14
Study 35020932 — intervention group
Group type: COMPARATOR
Intervention: Standardized mixed meal (498 kcal, 34E% fat, 49E% carbohydrate, 17E% protein)
Number of subjects: 14
Study 34836179 — intervention group
Group type: EXPERIMENTAL
Intervention: Western‐like diet high‐fat (WDHF) meal
Number of subjects: 49
Study 34836179 — intervention group
Group type: EXPERIMENTAL
Intervention: Western‐like diet high-carbohydrate (WDHC) meal
Number of subjects: 49
Study 34836179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean‐like diet (MED) meal
Number of subjects: 49
Study 34836179 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE E4 carriers
Number of subjects: 49
Study 35012592 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE with FFP2 mask with an expiration valve
Number of subjects: 48
Study 35012592 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE with FFP2 mask without an expiration valve
Number of subjects: 48
Study 35012592 — intervention group
Group type: COMPARATOR
Intervention: Control (without PPE)
Number of subjects: 48
Study 32903062 — intervention group
Group type: COMPARATOR
Intervention: White light emitting diodes
Number of subjects: 29
Study 32903062 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light emitting diodes
Number of subjects: 29
Study 36449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 30
Study 36449836 — intervention group
Group type: COMPARATOR
Intervention: 25% glucose
Number of subjects: 30
Study 33418429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level MAP (60–70 mmHg)
Number of subjects: 322
Study 33418429 — intervention group
Group type: COMPARATOR
Intervention: High-level MAP (90–100 mmHg)
Number of subjects: 322
Study 34216466 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine infiltration
Number of subjects: 50
Study 34216466 — intervention group
Group type: COMPARATOR
Intervention: Standard subcutaneous infiltration of dilute lidocaine solution
Number of subjects: 50
Study 32354366 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn CRP levels measured in cord blood
Number of subjects: 358
Study 32354366 — intervention group
Group type: COMPARATOR
Intervention: Maternal CRP levels measured during each trimester
Number of subjects: 358
Study 32354366 — intervention group
Group type: COMPARATOR
Intervention: Randomization to low dose aspirin prior to pregnancy
Number of subjects: 358
Study 36089738 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music intervention (listening to music of their choice for 30 minutes per session, three times per week for 5 weeks)
Number of subjects: 42
Study 36089738 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (no music for relaxation)
Number of subjects: 42
Study 34372746 — intervention group
Group type: EXPERIMENTAL
Intervention: New prolonged-release leuprorelin acetate microspheres for injection (3.75 mg)
Number of subjects: 48
Study 34372746 — intervention group
Group type: COMPARATOR
Intervention: Enantone® (3.75 mg)
Number of subjects: 48
Study 36030888 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff Vision (ECV)
Number of subjects: 1416
Study 36030888 — intervention group
Group type: COMPARATOR
Intervention: High-definition colonoscopies (control)
Number of subjects: 1416
Study 34952874 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of otitis media in Aboriginal and Torres Strait Islander children
Number of subjects: 67
Study 34952874 — intervention group
Group type: EXPERIMENTAL
Intervention: Research teams' long-term responsibility to deliver benefits to AMSs and communities
Number of subjects: 67
Study 33052400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous tropisetron before anesthesia induction
Number of subjects: 1508
Study 33052400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1508
Study 35322769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40 or 80 mg/day)
Number of subjects: 326
Study 35322769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 33145643 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal HP (high-protein diet with predominance of animal protein)
Number of subjects: 80
Study 33145643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable HP (high-protein diet with predominance of vegetable protein)
Number of subjects: 80
Study 33145643 — intervention group
Group type: COMPARATOR
Intervention: Animal NP (normal protein diet with predominance of animal protein)
Number of subjects: 80
Study 33145643 — intervention group
Group type: COMPARATOR
Intervention: Vegetable NP (normal protein diet with predominance of vegetable protein)
Number of subjects: 80
Study 36152382 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 2767
Study 36152382 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality and assigned sex (male)
Number of subjects: 2767
Study 33099812 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with HIFU (observation group)
Number of subjects: 132
Study 33099812 — intervention group
Group type: COMPARATOR
Intervention: TACE alone (control group)
Number of subjects: 132
Study 32669121 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fixation using volar locking plates
Number of subjects: 0
Study 32669121 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment using closed reduction and plaster immobilisation
Number of subjects: 0
Study 35057420 — intervention group
Group type: EXPERIMENTAL
Intervention: K-diet (traditional balanced Korean diet)
Number of subjects: 0
Study 35057420 — intervention group
Group type: COMPARATOR
Intervention: Control diet (westernized Korean control diet)
Number of subjects: 0
Study 35057420 — intervention group
Group type: EXPERIMENTAL
Intervention: K-diet
Number of subjects: 0
Study 35690316 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase‐5 inhibitors (PDE‐5i)
Number of subjects: 0
Study 33506054 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment for 2 weeks
Number of subjects: 0
Study 33506054 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 0
Study 33506054 — intervention group
Group type: COMPARATOR
Intervention: CRSwNP patients
Number of subjects: 0
Study 33506054 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 33506054 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐β1 and IL‐4 in cultured nasal tissues
Number of subjects: 0
Study 33506054 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐β1
Number of subjects: 0
Study 33506054 — intervention group
Group type: COMPARATOR
Intervention: Nasal polyp tissue of CRSwNP
Number of subjects: 0